Mepolizumab gains FDA nod for pediatric severe eosinophilic asthma | Elite Pharma's generic version of Tylenol with Codeine gains FDA nod | FDA approval granted to tenapanor for adult IBS with constipation
September 13, 2019
Bio SmartBrief
SIGN UP ⋅   FORWARD
Today's Top Story
Mepolizumab gains FDA nod for pediatric severe eosinophilic asthma
An expanded indication for GlaxoSmithKline's Nucala, or mepolizumab, gained the FDA's approval as a treatment for pediatric patients with severe eosinophilic asthma between the ages of 6 to 11. The subcutaneous injection received FDA approval in 2015 as a supplementary maintenance therapy for patients with severe asthma aged 12 years or older.
Medscape (free registration) (9/12) 
LinkedIn Twitter Facebook Email
Health Care & Policy
Elite Pharma's generic version of Tylenol with Codeine gains FDA nod
The FDA gave its approval for the generic version of Johnson & Johnson's Tylenol with Codeine, or acetaminophen and codeine phosphate, manufactured by Elite Pharmaceuticals. The generic tablets are available in various dosage strengths.
Seeking Alpha (9/12) 
LinkedIn Twitter Facebook Email
FDA approval granted to tenapanor for adult IBS with constipation
FDA approval granted to tenapanor for adult IBS with constipation
(Pixabay)
The FDA has approved Ardelyx's Ibsrela, or tenapanor, to treat adult irritable bowel syndrome with constipation, to be taken twice daily in 50-mg doses. Patients who have or are suspected of having mechanical gastrointestinal obstruction are not advised to take Ibsrela.
Medscape (free registration) (9/12) 
LinkedIn Twitter Facebook Email
 
Scotland seals access agreement with Vertex for cystic fibrosis drugs
A five-year access agreement was finalized between Scotland's Scottish Medicines Consortium and Vertex that will provide about 400 eligible Scottish patients with cystic fibrosis access to Symkevi, or tezacaftor and ivacaftor, and Orkambi, or lumacaftor and ivacaftor.
PharmaTimes online (UK) (9/12) 
LinkedIn Twitter Facebook Email
NICE approves BioMarin's Batten disease therapy; NHS to fund treatment
The UK's National Institute for Health and Care Excellence issued a positive recommendation for BioMarin's Brineura, or cerliponase alfa, for the treatment of the extremely rare inherited condition called Batten disease. Because of NICE's backing, the National Health Service announced it will now fund the treatment after reaching a pricing deal with BioMarin.
PMLive (UK) (9/12),  The Telegraph (London) (tiered subscription model) (9/11) 
LinkedIn Twitter Facebook Email
Company & Financial News
Jiangsu Hansoh, Atomwise enter drug discovery deal worth up to $1.5B
The Jiangsu Hansoh Pharmaceutical Group and Atomwise have partnered to design and discover possible treatments for up to 11 unnamed target proteins for oncologic and other therapeutic areas, a deal valued up to $1.5 billion. Atomwise uses artificial intelligence technology to help determine the binding capability of small molecules to a target protein.
Genetic Engineering & Biotechnology News (9/12) 
LinkedIn Twitter Facebook Email
$1B-plus deal to advance cell therapy candidate for chronic back pain
Mesoblast, an Australian cell therapy developer, will collaborate with the Grunenthal Group of Germany to advance development of its candidate, MPC-06-ID, an allogeneic cell therapy indicated for the treatment of discogenic chronic back pain. The deal grants Grunenthal exclusive development and marketing rights in Europe and Latin America, with Mesoblast eligible for an upfront payment of $150 million and over $1 billion in potential milestone payments.
BioPharmaReporter (9/12) 
LinkedIn Twitter Facebook Email
BioNTech's planned Nasdaq IPO valued at nearly $100M
BioNTech of Germany has submitted documents for its planned Nasdaq initial public offering and expects to raise almost $100 million, an amount much lower than analysts estimated. The funds will support future preclinical and clinical programs for cancer indications, which include chimeric antigen receptor T-cell therapies, messenger RNA drugs, T-cell receptors and others, as well as the expansion of its laboratories and manufacturing plants.
Labiotech (Germany) (9/12) 
LinkedIn Twitter Facebook Email
The Latest From BIO ...
BIO Business Solutions® knows the life science industry, and we put that expertise to work every day to deliver lab and business needs that help you save time and money. Learn more.
LinkedIn Twitter Facebook Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Food & Agriculture
Oxitec proposes to release biotech mosquitoes in the Fla. Keys
The government of Florida received a proposal from British firm Oxitec to test its biotech Aedes aegypti mosquitoes, a breed that normally transmits deadly diseases such as dengue and Zika, by releasing them in the Florida Keys to propagate with local mosquitoes. Oxitec's biotech mosquitoes are sterile and have been successfully tested in Jacobina, Brazil.
WUSF-FM (Tampa, Fla.) (9/12) 
LinkedIn Twitter Facebook Email
Industrial & Environmental
Australian project converts sugarcane, cotton into usable materials
The federal government of Australia will fund a midstage Queensland University of Technology project that converts sugarcane and cotton biomass into animal feed, fuels and bio-based plastics. Sugarcane waste is being converted into jet fuel, while chemicals produced from the biomass are being used to manufacture plastic beer and soft drink bottles.
Manufacturers' Monthly (Australia) (9/13) 
LinkedIn Twitter Facebook Email
News From BIO
We know you're busy, so we've done the research for you
BIO Business Solutions® assesses each preferred partner on a variety of criteria, including experience in the life sciences industry and customer support capabilities. You do not have to change the way you do business to enjoy the BIO discounts and other benefits! In most cases, the full selection of products and services offered by a BIO Business Solutions® supplier is available to you at a discounted price -- not just a short list of obscure closeout items. Learn more.
LinkedIn Twitter Facebook Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
  
  
Ditch the dream and be a doer, not a dreamer.
Shonda Rhimes,
television producer, writer
LinkedIn Twitter Facebook Email
  
  
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Sarah Hostetler
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information